At a glance
| Target | GLP-1 receptor |
|---|---|
| Origin of design | Exendin-4 sequence |
| Examples | Immediate-release exenatide; Bydureon BCise |
| Route | Subcutaneous injection |
| Distinct risk | Immune-mediated thrombocytopenia |
Overview
Exenatide was among the early GLP-1 medicines and is based on the exendin-4 peptide sequence. Shorter-acting products and extended-release microsphere products differ in exposure, eligibility and adverse-effect profiles. Brand discontinuation in a market should also be distinguished from the existence of a current generic or another formulation: a 2026 DailyMed label describes immediate-release exenatide injection. The medicine is used to improve glycemic control in type 2 diabetes, not as an established obesity drug or substitute for insulin in type 1 diabetes. The formulation is therefore part of the clinical identity, not a minor packaging detail.
How it works
Exenatide activates GLP-1 receptors and promotes insulin release when glucose is elevated, reduces inappropriate glucagon secretion and slows gastric emptying. It resists rapid breakdown by DPP-4 compared with native GLP-1. Renal clearance contributes to its exposure, which is one reason kidney function and dehydration matter. Sustained-release technology changes the duration of delivery without changing the underlying receptor target.
Formulation-specific populations
The current immediate-release generic label covers adult type 2 diabetes with diet and exercise. Extended-release labeling differs, including its pediatric population and additional precautions. One formulation’s label should not be used as a shortcut for another.
What established efficacy means
Registration studies demonstrate improved glycemic control in the specified diabetes settings. A reduction in HbA1c or body weight is not equivalent to proven benefit for unrelated neurologic diseases or to approval as a chronic obesity treatment.
Important adverse effects
Nausea and other gastrointestinal effects can lead to dehydration and kidney injury. Pancreatitis, gallbladder disease and serious hypersensitivity are recognized. Rare drug-induced immune-mediated thrombocytopenia can cause serious bleeding and is a contraindication to re-exposure when it has occurred.
Supporting sources [1]
Kidney function and concurrent treatment
The product label includes renal limitations and cautions. Insulin and insulin secretagogues increase hypoglycemia risk. Antibody formation can affect response, and persistent deterioration in glycemic control requires clinical reassessment rather than assuming inadequate appetite suppression.
Why older brand information can mislead
A historical brand listing does not establish current availability, and a brand withdrawal does not necessarily mean the ingredient lacks any approved presentation. The current authorized formulation and its label are the appropriate reference for clinical decisions.
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Exendin-4-based GLP-1 receptor agonist peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Exenatide injection current prescribing information, 2026 ↗Regulatory source · Checked 2026-10-27
- FDA: Bydureon BCise prescribing information ↗Regulatory source · Checked 2026-10-27